Most patients stay 4 weeks at each step before moving up
Its premise is an upstream intervention targeting substantial weight reduction to improve key risk factors with the aim to avoid potential downstream complications from multiple co-morbidities, e.g., hypertension, dyslipidaemia, heart failure, kidney disease, NAFLD/NASH or diabetes
While genetic variants do not predict exact medication response, they can support a more informed initial discussion with your healthcare provider about dosing strategy and tolerance expectations
Wegovy follows a more gradual escalation: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, with each step lasting 4 weeks
If you still cannot tolerate the maintenance dose of 2.4 mg once weekly, speak with your healthcare professional about decreasing the maintenance dose to 1.7 mg once a week